PIL
05/08/2015 09:48
GENERAL
PRICE SENSITIVE
REL: 0948 HRS Promisia Integrative Limited
GENERAL: PIL: Sales of Arthrem(R) increase by over 150%
Promisia's Chairman, Malcolm Johnson, announced today a large increase in the
average monthly sales since the company went public with positive preliminary
clinical trial findings in May. Sales of the company's flagship product
Arthrem(R) have increased by more than 150% compared to the previous 12 month
average monthly sales.
The Company's Chief Executive Charles Daily said: "We believe this is just
the beginning of the sales growth. It has always been a defining thrust of
our strategy to back our products with robust safety and efficacy data from
scientific research." Mr Daily went on to say: "There are quite a few
products on the market that are making exaggerated therapeutic claims. Our
point of difference will be the quality and transparency of our research."
For further information please contact:
Charles Daily, Chief Executive on (04) 894 8524 or
Malcolm Johnson, Chairman on (04) 479 3377
ENDS
End CA:00267944 For:PIL Type:GENERAL Time:2015-08-05 09:48:36
